Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

Yujia Jiang, Rong Wang, Jiazheng Guo, Kexuan Cheng, Lei Chen, Xi Wang, Yating Li, Peng Du, Gao Chen, Jiansheng Lu, Yun‐Zhou Yu, Zhixin YangFrontiers in Immunology 2024 · DOI

This research paper, published in Frontiers in Immunology (April 2024), describes the development of a new class of chimeric antibodies designed to neutralize Botulinum neurotoxin type B (BoNT/B), one of the most poisonous substances known to science.

TL;DR

Researchers have engineered three high-affinity chimeric antibodies (B5-hFc, B9-hFc, and B12-hFc) by fusing camel-derived nanobodies with human Fc fragments. These antibodies demonstrate potent neutralizing activity against Botulinum neurotoxin type B in mouse models, offering a promising, safer alternative to traditional horse-serum-based antitoxins.

What Problem Does This Paper Address?

Botulinum neurotoxins (BoNTs) are lethal proteins produced by Clostridium botulinum that cause botulism, a severe paralytic disease. BoNT/B is one of the primary serotypes responsible for human cases and is considered a significant biosecurity threat.

Currently, the "gold standard" for treatment is polyvalent horse serum antitoxin. However, these equine-derived products carry a high risk of adverse reactions (like serum sickness or anaphylaxis) and suffer from supply chain instabilities. While monoclonal antibodies (mAbs) are a modern alternative, they are often expensive and difficult to produce. This paper explores nanobodies—the tiny, single-domain variable fragments found in camelids—as a more stable, highly specific, and easier-to-engineer platform for toxin neutralization.

Methods

The authors employed a multi-step "biopanning" and engineering approach:

  1. Immunization: A Bactrian camel was immunized with the recombinant Hc domain of BoNT/B (the part of the toxin responsible for binding to nerve cells).
  2. Library Construction: The researchers built a phage display library containing over 400 million unique nanobody (VHH) sequences derived from the camel’s B cells.
  3. Screening: Through three rounds of competitive binding assays, they identified 72 unique nanobody sequences that specifically targeted the BoNT/B Hc domain.
  4. Chimerization: To prevent the tiny nanobodies from being rapidly cleared by the kidneys, the authors fused the best-performing VHH sequences with a human Fc fragment (hFc). This created "chimeric heavy chain antibodies" that are larger, more stable, and more compatible with the human immune system.
  5. Validation: The antibodies were tested for affinity using Biolayer Interferometry (BLI) and for protective efficacy in live mouse models (both prophylactic and therapeutic).

Datasets

The study utilized several biological "datasets" and benchmarks:

  • Phage Display Library: A custom-built library of $4 \times 10^8$ colony-forming units (CFU).
  • Recombinant Proteins: A panel of Hc proteins from different BoNT serotypes (A, B, E, F) and Tetanus toxin (TeNT) used to prove the antibodies' high specificity.
  • In Vivo Benchmarks: The standard "Gold Standard" equine antitoxin (BAT-B) was used as a positive control for neutralization potency.

Key Insights and Ideas

  • Size Matters: Nanobodies are excellent at finding "hidden" epitopes on toxins that larger, conventional antibodies might miss. However, their small size is a double-edged sword because they are excreted too quickly. By adding the human Fc tail, the authors successfully combined camelid precision with human-like longevity in the bloodstream.
  • Blocking the "Key": The Hc domain is essentially the "key" the toxin uses to unlock and enter neurons. The study confirms that targeting this specific domain is an exceptionally efficient strategy for neutralization—if the toxin can't bind to the receptor, it can't cause paralysis.
  • Extreme Potency: One of the lead candidates, B9-hFc, showed remarkable strength. It provided 50% protection at a dose of just 0.1 $\mu$g against a 20x $LD_{50}$ (lethal dose) challenge in mice.

Key Results

  • High Affinity: The three lead antibodies (B5, B9, B12) showed equilibrium dissociation constants ($K_D$) in the nanomolar range (4.51 nM to 12.2 nM), indicating very tight binding to the toxin.
  • Prophylactic Success: In mice, pre-treatment with these antibodies provided 100% protection against lethal toxin doses for up to three days post-injection.
  • Therapeutic Window: Most impressively, the antibodies remained effective even when administered 3 hours after the mice were exposed to the toxin, suggesting they could be used in emergency clinical settings.
  • Specificity: ELISA results showed zero cross-reactivity with other BoNT types (A, E, F) or Tetanus, reducing the risk of off-target effects.

Limitations and Future Work

While the results are promising, the authors acknowledge a few hurdles:

  • Single-Epitope Risk: Using a single monoclonal antibody might be risky if the toxin mutates or if different strains of BoNT/B have slightly different Hc structures.
  • The "Cocktail" Approach: The authors suggest that future work should focus on creating "multivalent" or "multispecific" antibodies—essentially combining several of these nanobodies into a single drug to cover more surface area on the toxin and increase potency further.
  • Structural Mapping: The exact "footprint" of where these antibodies bind on the toxin is still unknown. Future studies using X-ray crystallography or Cryo-EM are needed to visualize the binding interface at an atomic level.

Summary updated

Abstract

The results demonstrate that inhibiting toxin binding to the host receptor is an efficient strategy and the three antibodies could be used as candidates for the further development of drugs to prevent and treat botulism.
BibTeX
@inproceedings{jiang2024isolation,
  author = {Yujia Jiang and Rong Wang and Jiazheng Guo and Kexuan Cheng and Lei Chen and Xi Wang and Yating Li and Peng Du and Gao Chen and Jiansheng Lu and Yun‐Zhou Yu and Zhixin Yang},
  title = {{Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1380694},
}
Figure